Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abiomed Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Revenue
Cost of revenue
Gross profit
Research and development
Selling, general and administrative
Acquired in-process research and development
Income (loss) from operations
Interest and other income (expense), net
Income (loss) before income taxes
Income tax (provision) benefit
Net income (loss)

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).


Revenue Trend
Revenue demonstrates a generally upward trajectory from mid-2016 through mid-2022, increasing from approximately $103 million to a peak near $277 million. Notable quarterly jumps are observed toward late 2017 and persistently high levels through 2021, followed by minor fluctuations but overall sustained growth despite occasional dips.
Cost of Revenue Pattern
The cost of revenue follows a similar growth pattern to revenue, rising from around $15 million to about $52 million over the period. Increases are steady with occasional spikes, especially in late 2018 and early 2022, reflecting higher expenses correlating with overall sales growth.
Gross Profit Development
Gross profit shows steady growth aligned with revenue and cost trends, escalating from roughly $88 million to over $217 million. Variability exists, with some slower growth periods, notably around 2020, likely influenced by expense fluctuations and market conditions.
Research and Development (R&D) Expenses
R&D expenses exhibit a consistent upward trend, growing from about $15.7 million to over $42 million. This indicates sustained investment in innovation and product development, with pronounced increases post-2019, suggesting strategic prioritization of research activities.
Selling, General and Administrative (SG&A) Expenses
SG&A costs increase moderately from roughly $51 million to approximately $117 million over the dataset period. The expenses grow steadily, with some volatility, particularly marked increases after 2018, reflecting expanding operational or marketing efforts concurrent with revenue growth.
Acquired In-Process Research and Development
A significant one-time charge appears in March 2021, amounting to approximately $115 million, representing a non-recurring acquisition-related expense. Additional smaller charges occur intermittently, indicating sporadic strategic investments or acquisitions in research capabilities.
Operating Income Dynamics
Operating income generally trends upward, starting from about $21 million and reaching over $65 million by 2022, with fluctuations that correspond to changes in gross profit and operating expenses. A sharp drop to a loss near negative $49 million is seen in late 2021, likely due to the aforementioned acquisition expense.
Interest and Other Income (Expense)
This category shows substantial volatility, with usual amounts under a few million dollars but several extraordinary spikes, including a $33 million gain in early 2019 and a large $81 million gain in late 2022. There are also notable negative swings, signifying variable investment returns or financial transactions impacting net income.
Income Before Taxes
Income before taxes mostly matches operating income trends supported by interest income variations, fluctuating broadly from approximately $21 million up to a peak of $139 million in late 2022. The period includes several quarters of steep rises and declines, reflecting the irregular nature of other income and extraordinary items.
Income Tax Provision
Income tax provisions alternate between positive and negative values, with significant spikes in charges during periods of higher income before taxes, reflecting tax obligations tied to profitability. Occasional tax benefits coincide with losses or low income periods, contributing to net income variability.
Net Income Movements
Net income exhibits substantial growth and volatility, rising from roughly $13 million in mid-2016 to over $106 million by late 2022. Several steep increases correspond to large non-operational gains or tax adjustments. A notable net loss occurs in late 2021, linked to acquisition-related expenses impacting operating income.